Match!
Elin S. Gray
Edith Cowan University
Molecular biologyVirologyAntibodyEpitopeBiology
86Publications
31H-index
3,713Citations
What is this?
Publications 96
Newest
#1Jenny H. Lee (Macquarie University)H-Index: 9
#2Alexander M. Menzies (USYD: University of Sydney)H-Index: 36
Last. Michael Millward (UWA: University of Western Australia)H-Index: 45
view all 17 authors...
PURPOSE: Brain involvement occurs in majority of patients with metastatic melanoma. The potential of circulating tumor DNA (ctDNA) for surveillance and monitoring systemic therapy response in patients with melanoma brain metastases merits investigation. EXPERIMENTAL DESIGN: This study examined circulating BRAF, NRAS and c-KIT mutations in melanoma patients with active brain metastases receiving PD-1 inhibitor-based therapy. Intracranial and extracranial disease volumes were measured using the su...
Source
#1Bella Hai Nguyen (UWA: University of Western Australia)
#2Katie Meehan (CUHK: The Chinese University of Hong Kong)
Last. Andrew Lindsay (Hollywood Private Hospital)
view all 14 authors...
Purpose: This study compares the detection sensitivity of two separate liquid biopsy sources, cell-free (cf) DNA/RNA and extracellular vesicle (EV)-associated DNA/RNA (EV-DNA/RNA), to identify circulating Human Papilloma Virus (HPV) DNA/RNA in plasma obtained from patients with oropharyngeal squamous cell carcinoma (OPCSCC). We also report on the longitudinal changes observed in HPV-DNA levels in response to treatment. Experimental design: A prospective study was conducted that included 22 patie...
Source
#1Muhammad A. Khattak (ECU: Edith Cowan University)H-Index: 7
#2Anna L. Reid (ECU: Edith Cowan University)H-Index: 5
Last. Elin S. Gray (ECU: Edith Cowan University)H-Index: 31
view all 14 authors...
BACKGROUND: PD-1 inhibitors are routinely used for the treatment of advanced melanoma. This study sought to determine whether PD-L1 expression on circulating tumor cells (CTCs) can serve as a predictive biomarker of clinical benefit and response to treatment with the PD-1 inhibitor pembrolizumab. METHODS: Blood samples were collected from patients with metastatic melanoma receiving pembrolizumab, prior to treatment and 6-12 weeks after initiation of therapy. Multiparametric flow cytometry was us...
Source
#1Carlos A. Aya-Bonilla (ECU: Edith Cowan University)H-Index: 2
#2Michael Morici (ECU: Edith Cowan University)H-Index: 4
Last. Michael Millward (UWA: University of Western Australia)H-Index: 45
view all 12 authors...
Circulating tumour cells (CTCs) can be assessed through a minimally invasive blood sample with potential utility as a predictive, prognostic and pharmacodynamic biomarker. The large heterogeneity of melanoma CTCs has hindered their detection and clinical application. Here we compared two microfluidic devices for the recovery of circulating melanoma cells. The presence of CTCs in 43 blood samples from patients with metastatic melanoma was evaluated using a combination of immunocytochemistry and t...
Source
#1Aaron Beasley (ECU: Edith Cowan University)H-Index: 1
#2Jacqueline M. Bentel (Fiona Stanley Hospital)H-Index: 20
Last. Elin S. Gray (ECU: Edith Cowan University)H-Index: 31
view all 9 authors...
Abstract Analysis of specific somatic copy number alterations (SCNAs) using multiplex ligation-dependent probe amplification (MLPA) is routinely used as prognostic test for uveal melanoma (UM). This technique requires relatively large amounts of input DNA, unattainable from many small fine needle aspirate biopsies. Herein we compared the use of MLPA with whole genome amplification (WGA) combined with low-pass whole genome sequencing (LP-WGS) for detection of SCNA profiles in UM biopsy specimens....
Source
#1Du-Bois Asante (ECU: Edith Cowan University)H-Index: 1
#2Leslie Calapre (ECU: Edith Cowan University)H-Index: 6
Last. Elin S. Gray (ECU: Edith Cowan University)H-Index: 31
view all 5 authors...
Abstract Liquid biopsies hold the potential to inform cancer patient prognosis and to guide treatment decisions at the time when direct tumor biopsy may be impractical due to its invasive nature, inaccessibility and associated complications. Specifically, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have shown promising results as companion diagnostic biomarkers for screening, prognostication and/or patient surveillance in many cancer types. In ovarian cancer (OC), CTC and ct...
2 CitationsSource
#1Leslie Calapre (ECU: Edith Cowan University)H-Index: 6
#2Lydia Warburton (SCGH: Sir Charles Gairdner Hospital)H-Index: 3
Last. Elin S. Gray (UWA: University of Western Australia)H-Index: 31
view all 4 authors...
Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. The presence of ctDNA in the blood is a result of biological processes, namely tumour cell apoptosis and/or necrosis, and can be used to monitor different cancers by targeting cancer-specific mutation. We present the case of a 67 year old Caucasian male that was initially treated with BRAF inhibitors followed by anti-CTLA4 and then anti-PD1 immunotherap...
Source
#1Mitchell S. Stark (UQ: University of Queensland)H-Index: 31
#2Elin S. Gray (ECU: Edith Cowan University)H-Index: 31
Last. Nicholas K. Hayward (QIMR: QIMR Berghofer Medical Research Institute)H-Index: 83
view all 15 authors...
To determine if a circulating microRNA (miRNA) panel could be used to distinguish between uveal melanoma and uveal nevi. We report on a multicenter, cross-sectional study conducted between June 2012 and September 2015. The follow-up time was approximately 3 to 5 years. Blood was drawn from participants presenting with a uveal nevus ( = 10), localized uveal melanoma ( = 50), or metastatic uveal melanoma ( = 5). Levels of 17 miRNAs were measured in blood samples of study participants using a sensi...
Source
#1A. Abed (Fiona Stanley Hospital)
#2Adnan Khattak (Fiona Stanley Hospital)H-Index: 1
Last. Elin S. Gray (ECU: Edith Cowan University)H-Index: 31
view all 5 authors...
Background: We aimed to assess the role of genomic HLA‐I/II heterozygosity in the overall survival benefit in patients with unresectable locally advanced, metastatic non‐small lung cancer treated by PD1/L1 inhibitors...
Source
#1L. Barrett (UWA: University of Western Australia)H-Index: 4
#2Elin S. Gray (ECU: Edith Cowan University)H-Index: 31
Last. Jason Waithman (UWA: University of Western Australia)H-Index: 19
view all 4 authors...
Source
12345678910